Monday 24 February 2020 ,
Monday 24 February 2020 ,
Latest News
  • GP pays BTRC Tk 1,000cr
  • HC seeks report on Khaleda’s health condition
  • Angelina Jolie appreciates Bangladesh’s leadership role in Rohingya crisis
  • 18 injured as private car ploughs through crowd in Kurmitola
  • Khaleda to be granted bail, hopes Fakhrul
  • Appellate Division upholds bail of Sigma Huda, two daughters
  • FM hopeful of reopening labour market in Malaysia soon
  • Shanto, Mominul hit fifties as Tigers trail by 25 runs
19 August, 2019 00:00 00 AM

FDA approves Pretomanid for highly drug-resistant forms of tuberculosis

TB Alliance
FDA approves Pretomanid for highly drug-resistant forms of tuberculosis

Pretomanid, a novel compound developed by the non-profit organization TB Alliance, was approved by the U.S. Food & Drug Administration (FDA) recently for treating some of the most drug-resistant forms of tuberculosis (TB). The new drug was approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD pathway) as part of a three-drug, six-month, all-oral regimen for the treatment of people with extensively drug-resistant TB (XDR-TB) or multidrug-resistant TB (MDR-TB) who are treatment-intolerant or non-responsive (collectively “highly drug-resistant TB”).

The LPAD pathway was established by FDA as a tool to encourage further development of antibacterial and antifungal drugs to treat serious, life-threatening infections that affect a limited population of patients with unmet needs.

“FDA approval of this treatment represents a victory for the people suffering from these highly drug-resistant forms of the world’s deadliest infectious disease,” said Mel Spigelman, MD, president and CEO of TB Alliance. “The associated novel regimen will hopefully provide a shorter, more easily manageable and highly efficacious treatment for those in need.”

The three-drug regimen consisting of bedaquiline, pretomanid and linezolid – collectively referred to as the BPaL regimen – was studied in the pivotal Nix-TB trial across three sites in South Africa. The trial enrolled 109 people with XDR-TB as well as treatment-intolerant or non-responsive MDR-TB.

Nix-TB data have demonstrated a successful outcome in 95 of the first 107 patients after six months of treatment with BPaL and six months of post-treatment follow-up. For two patients, treatment was extended to nine months. The new drug application contains data on 1,168 people who have received pretomanid in 19 clinical trials that have evaluated the drug’s safety and efficacy. Pretomanid has been clinically studied in 14 countries.

TB, in all forms, must be treated with a combination of drugs; the most drug-sensitive forms of TB require six months of treatment using four anti-TB drugs.3 Treatment of XDR-TB or treatment-intolerant/non-responsive MDR-TB has historically been lengthy and complex; most XDR-TB patients currently take a combination of as many as eight antibiotics, some involving daily injections, for 18 months or longer. Prior to recent introduction of new drugs for drug-resistant TB, the World Health Organization (WHO) has reported estimates for treatment success rates of XDR-TB therapy at approximately 34 percent and about 55 percent for MDR-TB therapy.

“Until very recently, people infected with highly drug-resistant TB had poor treatment options and a poor prognosis,” said Dr. Francesca Conradie, principal investigator of the Nix-TB trial. “This new regimen provides hope with 9 out of 10 patients achieving culture negative status at 6 months post-treatment with this short, all-oral regimen."

Pretomanid is a new chemical entity and a member of a class of compounds known as nitroimidazooxazines. TB Alliance acquired the developmental rights to the compound in 2002. It has been developed as an oral tablet formulation for the treatment of TB in combination with bedaquiline and linezolid, two other anti-TB agents, and is now indicated for use in a limited and specific population of patients. Adverse reactions reported during the Nix-TB trial of the BPaL regimen include hepatotoxicity, myelosuppression, as well as peripheral and optic neuropathy. Please see additional safety information in the Important Safety Information below.

Pretomanid is only the third new anti-TB drug approved for use by FDA in more than 40 years, as well as the first to be developed and registered by a not-for-profit organization. Pretomanid was granted Priority Review, Qualified Infectious Disease Product, and Orphan Drug status. As a product development partnership, TB Alliance has collaborated with and received significant support from numerous governments, academia, philanthropic institutions, the private sector, civil society organizations and other partners over the course of pretomanid’s development.

Indication

Limited Population: Pretomanid Tablet is an antimycobacterial indicated, as part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary extensively drug-resistant (XDR), treatment-intolerant or non-responsive multidrug resistant (MDR) tuberculosis (TB).  Approval of this indication is based on limited clinical safety and efficacy data.  This drug is indicated for use in a limited and specific population of patients.

Limitations of Use:

Pretomanid Tablets are not indicated for patients with:

Drug-sensitive (DS) tuberculosis

Latent infection due to Mycobacterium tuberculosis

Extra-pulmonary infection due to Mycobacterium tuberculosis

MDR-TB that is not treatment-intolerant or non-responsive to standard therapy

Safety and effectiveness of Pretomanid Tablets have not been established for its use in combination with drugs other than bedaquiline and linezolid as part of the recommended dosing regimen.

 

Important safety information

Contraindications

Pretomanid Tablets used in combination with bedaquiline and linezolid are contraindicated in patients for whom bedaquiline and/or linezolid is contraindicated.

Warnings and Precautions

Hepatic adverse reactions were reported with the use of the combination regimen of Pretomanid Tablets, bedaquiline, and linezolid.  Monitor symptoms and signs and liver related laboratory tests.  Interrupt treatment with the entire regimen if evidence of liver injury occurs.

Myelosuppression was reported with the use of the combination regimen of Pretomanid Tablets, bedaquiline, and linezolid.  Monitor complete blood counts.  Decrease or interrupt linezolid dosing if significant myelosuppression develops or worsens.

Peripheral and optic neuropathy were reported with the use of the combination regimen of Pretomanid Tablets, bedaquiline, and linezolid.  Monitor visual function.  Obtain an ophthalmologic evaluation if there are symptoms of visual impairment.  Decrease or interrupt linezolid dosing if neuropathy develops or worsens.

QT prolongation was reported with the use of the combination regimen of Pretomanid Tablets, bedaquiline, and linezolid.  Use with drugs that prolong the QT interval may cause additive QT prolongation.  Monitor ECGs.  Discontinue the combination regimen of Pretomanid Tablets, bedaquiline, and linezolid if significant ventricular arrhythmia or if QTcF interval prolongation of greater than 500 ms develops.

Reproductive effects: Pretomanid caused testicular atrophy and impaired fertility in male rats. Advise patients of reproductive toxicities in animal studies and that the potential effects on human male fertility have not been adequately evaluated.

Lactic acidosis was reported with the use of the combination regimen of Pretomanid Tablets, bedaquiline, and linezolid.  Consider interrupting linezolid or the entire combination regimen of Pretomanid Tablets, bedaquiline, and linezolid dosing if significant lactic acidosis develops.

Adverse reactions

Most common adverse reactions (≥10%) are peripheral neuropathy, acne, anemia, nausea, vomiting, headache, increased transaminases, dyspepsia, decreased appetite, rash, pruritus, abdominal pain, pleuritic pain, increased gamma-glutamyltransferase, lower respiratory tract infection, hyperamylasemia, hemoptysis, back pain, cough, visual impairment, hypoglycemia, abnormal loss of weight, and diarrhea.

About tuberculosis

Tuberculosis is a global disease, found in every country in the world. It is the leading infectious cause of death worldwide. In 2017, 10 million people fell ill from active TB and 1.6 million died. It is an airborne disease that can be spread by coughing or sneezing. There are more than half a million cases of MDR-TB annually, with about 6% of those cases being XDR-TB. Current WHO figures report that 127 countries have reported cases of XDR-TB. Drug-resistant forms of TB currently accounts for close to 1 in 3 deaths due to antimicrobial resistance annually.

 

Comments

Most Viewed
Digital Edition
More story
Editor Speaks

Editor Speaks

15-20 cm long partly exocrine (digestive juice) and partly endocrine (insulin) Pancreas means all flesh (Pan=all, Kreas=flesh) which lies behind peritoneum…
What can doctors do for your back pain? Not as much as you can

What can doctors do for your back pain? Not as much as you can

“I’m sorry you’re in pain.” “You have no idea,” she growls. She is a middle-aged, obese woman with chronic back pain…
Everything you need to know about pancreatitis

Everything you need to know about pancreatitis

Pancreatitis is pathologic inflammation of the pancreas. Your pancreas sits behind your stomach, near your small intestine. It releases enzymes that help…
Acute pancreatitis risks and treatment

Acute pancreatitis risks and treatment

Risk stratification of acute pancreatitis In most cases, acute pancreatitis resolves with therapy, but approximately 15% of patients develop severe disease.3…
Alcohol, loneliness & other surprising things that spike your blood pressure

Alcohol, loneliness & other surprising things that spike your blood pressure

STEPHANIE ECKELKAMP They don’t call high blood pressure a “silent killer” for nothing. Turns out, about half of Americans have this…
Knowing the warning signs and symptoms of congenital atrial septal defect (ASD)

Knowing the warning signs and symptoms of congenital atrial septal defect (ASD)

The statistical data reveals that the average incidence rate of congenital heart defects reported in different studies is 1 up to 8 per 1,000 live births.…
Coronavirus and its symptoms

Coronavirus and its symptoms

JAMES GALLAGHER A virus causing severe lung disease that started in China has spread to other countries, including the UK. The coronavirus had infected…
Common causes of waking to urinate at night

Common causes of waking to urinate at night

BRANDON PETERS, MD If you wake during the night to pee, you may be interested in learning about the common causes of this occurrence. What is nocturia?…
Wheeze, asthma risk up with cleaning product use exposure in infancy

Wheeze, asthma risk up with cleaning product use exposure in infancy

Infants in homes with frequent use of household cleaning products have an increased risk for childhood wheeze and asthma, according to a study published…
Healthy 'Mediterranean Diet' is good for your microbiome

Healthy 'Mediterranean Diet' is good for your microbiome

The so-called Mediterranean diet is already considered one of the healthiest for your heart, and now scientists say it may give your gut bacteria a boost,…
U.S. scientists take key step towards Coronavirus vaccine

U.S. scientists take key step towards Coronavirus vaccine

There's been a crucial move forward in efforts to develop vaccines and treatments against the new COVID-19 coronavirus, U.S. researchers say. As of…
FDA approves Twirla (levonorgestrel and ethinyl estradiol) contraceptive patch

FDA approves Twirla (levonorgestrel and ethinyl estradiol) contraceptive patch

Agile Therapeutics, Inc.,  a forward-thinking women’s healthcare company, recently announced that the U.S. Food and Drug Administration (FDA)…

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting